Stanford Found a "Natural Ozempic" Using AI
A tiny 12-amino-acid peptide called BRP may curb appetite like semaglutide, without the nausea or muscle loss. Stanford researchers used AI to find it.
A team at Stanford Medicine just identified a molecule that reduces appetite like Ozempic but may skip many of its worst side effects. The molecule is a naturally occurring peptide called BRP, and artificial intelligence played a central role in finding it.
The study, published in Nature on April 12, 2026, is generating serious buzz. Here's what the research actually found, and what it might mean for weight management going forward.
What is BRP?
BRP is a small peptide made of just 12 amino acids. It comes from a parent molecule called BRINP2, which the body produces naturally. In lab tests, BRP activated appetite-regulating brain cells ten times more strongly than GLP-1, the hormone that drugs like semaglutide (Ozempic) are designed to mimic.
Key Takeaway: BRP is a naturally occurring 12-amino-acid peptide that activated appetite-regulating neurons ten times more strongly than GLP-1 in laboratory tests.
What makes BRP different from semaglutide is where it works. Ozempic binds to receptors scattered across the brain, gut, and pancreas. That broad reach explains both its effectiveness and its side effects, including nausea, constipation, and the muscle loss that concerns many users. BRP appears to target only the hypothalamus, the brain region that controls hunger and metabolism.
How AI found the needle in the haystack
The human body produces thousands of prohormones, which are large inactive molecules that get cut into smaller peptides. Some of those fragments act as hormones. Most are biological noise. Telling them apart using traditional lab methods is slow and unreliable.
The Stanford team built a computational tool called Peptide Predictor. It scanned all 20,000 human protein-coding genes to map where prohormones could be sliced into active peptides. From that scan, the algorithm flagged 2,683 candidates. Researchers then narrowed the pool to 100 for lab testing.
Stat: Peptide Predictor screened all 20,000 human protein-coding genes and identified 2,683 candidate peptides, from which researchers selected 100 for laboratory testing.
GLP-1 was included in the test batch as a benchmark. It performed well. But BRP outperformed it by a wide margin, boosting neuron activity tenfold compared to controls.
"The algorithm was absolutely key to our findings," said Katrin Svensson, assistant professor of pathology at Stanford and senior author of the study.
Animal results look promising
In lean mice, a single BRP injection before feeding cut food intake by up to 50% within an hour. In obese mice, two weeks of daily injections led to about 3 grams of weight loss (primarily fat), while untreated mice gained roughly the same amount. The treated animals also showed better glucose and insulin tolerance.
Minipigs, which metabolize food more similarly to humans than mice do, also ate significantly less after receiving BRP.
Key Takeaway: In obese mice, 14 days of BRP injections produced roughly 3 grams of fat loss and improved glucose tolerance, without affecting movement, water intake, or digestion.
Perhaps most importantly, the researchers found no changes in movement patterns, water intake, anxiety, or digestive function. Additional testing confirmed that BRP works through different brain pathways than GLP-1 or semaglutide. That distinction matters, because it suggests the two approaches could potentially complement each other.
What this doesn't mean (yet)
BRP has only been tested in animals so far. The jump from mice and minipigs to humans is significant, and plenty of promising molecules have failed at that stage. The researchers are still identifying which specific receptors BRP binds to, and they need to figure out how to extend its effects for practical use. Right now, a single injection wears off relatively quickly.
Svensson has co-founded a company to pursue human clinical trials, which adds both momentum and a financial conflict to be aware of.
"Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight," Svensson said. "We are very eager to learn if it is safe and effective in humans."
Why this matters for everyday nutrition
Whether BRP eventually becomes a drug or not, the study highlights something increasingly clear: appetite regulation is more complex than calories in versus calories out. The brain circuits that control hunger respond to specific molecular signals, and understanding those signals is advancing quickly.
For people managing their weight right now, the practical takeaway hasn't changed. Consistent tracking of what you eat gives you the data to understand your patterns. Adequate protein intake helps with satiety. Getting enough fiber supports the gut-brain communication that molecules like BRP tap into.
The science of appetite is getting more sophisticated. But the fundamentals of paying attention to your nutrition still form the foundation that any future breakthrough will build on.
FAQ
What is BRP, the "natural Ozempic" peptide?
BRP is a 12-amino-acid peptide discovered by Stanford researchers using AI. It occurs naturally in the human body and appears to suppress appetite by acting specifically on the hypothalamus. In animal studies, it reduced food intake without causing nausea, constipation, or muscle loss reported with semaglutide.
How did AI help discover BRP?
Researchers built an algorithm called Peptide Predictor that scanned all 20,000 human protein-coding genes to identify where inactive prohormones could be cut into active peptides. The tool flagged 2,683 candidates, from which BRP was identified as the strongest activator of appetite-regulating neurons.
Is BRP available as a drug?
No. BRP has only been tested in mice and minipigs as of April 2026. Human clinical trials have not yet started, though the lead researcher has co-founded a company to pursue them. It will likely take several years before any human treatment could become available.
How is BRP different from Ozempic?
Ozempic (semaglutide) mimics GLP-1 and binds to receptors throughout the body, including the gut and pancreas. BRP appears to act only on the hypothalamus in the brain. This narrower targeting may explain why animal studies showed fewer side effects, though human testing is still needed.
Can tracking nutrition help with appetite management?
Yes. Consistent meal tracking helps identify patterns in hunger, fullness, and macronutrient balance. Adequate protein and fiber intake have both been associated with better satiety in research studies. These practical habits remain relevant regardless of future pharmaceutical developments.
-- Selena